<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3213">
  <stage>Registered</stage>
  <submitdate>22/06/2011</submitdate>
  <approvaldate>22/06/2011</approvaldate>
  <nctid>NCT01384383</nctid>
  <trial_identification>
    <studytitle>GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype</studytitle>
    <scientifictitle>A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-248-0121</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GS-5885
Treatment: drugs - GS-9451
Treatment: drugs - RBV
Treatment: drugs - PEG

Experimental: Arm 1 - Response-Guided Therapy with GS-5885 30 mg plus GS-9451 200 mg, plus PEG and RBV for 6 or 12 weeks.

Experimental: Arm 2 - Response-Guided Therapy with PEG and RBV for 24 weeks.


Treatment: drugs: GS-5885
GS-5885 30 mg tablet administered orally once daily

Treatment: drugs: GS-9451
GS-9451 200 mg tablet administered orally once daily

Treatment: drugs: RBV
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75kg = 1000 mg and = 75 kg = 1200 mg)

Treatment: drugs: PEG
Pegylated interferon alfa-2a (PEG) 180 µg administered once weekly by subcutaneous injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained virologic response (SVR) - Sustained virologic response (SVR, defined as plasma HCV RNA &lt; lower limit of quantification [LLoQ] at 24 weeks after treatment cessation) following treatment with GS-5885 + GS-9451 + PEG/RBV for 6 or 12 weeks, or PEG/RBV for 24 weeks in IL28B CC subjects.</outcome>
      <timepoint>30 , 36 or 48 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of therapy - Safety and tolerability of the therapy is measured by frequency of laboratory abnormalities , reported adverse events and discontinuations due to adverse events.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic response - Virologic response at Weeks 2, 4, 6, 8, 10, and 12 (depending on treatment arm) as measured by the rates of HCV RNA &lt; LLoQ and viral breakthrough and relapse</outcome>
      <timepoint>Weeks 2, 4, 6, 8, 10, and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare SVR - Compare SVR following treatment with GS-5885 + GS-9451 + PEG/RBV for 6 weeks versus 12 weeks.</outcome>
      <timepoint>Weeks 30 and 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Viral resistance - Characterize viral resistance to GS-5885 and GS-9451 when administered in combination with PEG/RBV</outcome>
      <timepoint>Up to 96 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males and females 18-70 years of age

          -  Chronic HCV infection

          -  Subjects must have liver biopsy results (= 3 years prior to screening) indicating the
             absence of cirrhosis. Alternatively a non-invasive alternative to liver biopsy (such
             as FibroTest, FibroScan, or Acoustic Radiation Force Impulse imaging) within 6 months
             of Screening in countries where allowed

          -  Monoinfection with HCV genotype 1a or 1b

          -  HCV RNA &gt; 10^4 IU/mL at Screening

          -  IL28B CC genotype

          -  HCV treatment naïve

          -  Candidate for PEG/RBV therapy

          -  Body mass index (BMI) between 18 and 36 kg/m2

          -  Creatinine clearance &gt;= 50 mL/min

          -  Agree to use two forms of highly effective contraception methods for the duration of
             the study and for 7 months after the last dose study medication. Females of
             childbearing potential must have negative pregnancy test at Screening and Baseline</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Exceed defined thresholds for key laboratory parameters at Screening

          -  Diagnosis of autoimmune disease, decompensated liver disease, poorly controlled
             diabetes mellitus, significant psychiatric illness, severe chronic obstructive
             pulmonary disease (COPD), HIV, hepatitis B virus (HBV), hepatocellular carcinoma or
             other malignancy (with exception of certain skin cancers), hemoglobinopathy, retinal
             disease, or are immunosuppressed

          -  Subjects with current use of amphetamines, cocaine, opiates (e.g., morphine, heroin),
             or ongoing alcohol abuse are excluded. Subjects on stable methadone maintenance
             treatment for at least 6 months prior to Screening may be included into the study

          -  Use of prohibited concomitant medications two weeks prior to baseline through the end
             of treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>248</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Concord Repatriation General Hospital - Concord</hospital>
    <hospital>Saint Vincents Hospital - Darlinghurst</hospital>
    <hospital>Nepean Hospital - Kingswood</hospital>
    <hospital>St. George Hospital - Kogarah</hospital>
    <hospital>Liverpool Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Brisbane Hospital Research Foundation - Herston</hospital>
    <hospital>Greenslopes Private Hospital - Woolloongabba</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>St. Vincent's Hospital, Sydney Ltd. - Fitzroy</hospital>
    <hospital>Western Hospital - Footscray</hospital>
    <hospital>Austin Health, Department of Hepatology - Heidelberg</hospital>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Box Hill Hospital - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Fremantle Hospital - Fremantle</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2137 - Concord</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2747 - Kingswood</postcode>
    <postcode>NSW 2217 - Kogarah</postcode>
    <postcode>1871 - Sydney</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>VIC 3011 - Footscray</postcode>
    <postcode>3081 - Heidelberg</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3128 - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Aukland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, randomized, open-label exploratory study that will examine the antiviral
      efficacy, safety, and tolerability of Response guided treatment (RGT) with GS-5885 + GS-9451
      + PEG/RBV (6 or 12 weeks), or Peginterferon Alfa 2a (PEG)/Ribavirin (RBV)alone (24 weeks) in
      treatment naïve subjects with chronic Hep C (HCV) infection with genotype (GT) 1 and IL28B CC
      genotype.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01384383</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>